CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Biosimilar Infliximab in inflammatory bowel diseases: First interim results from a prospective nationwide observational cohort
DOI 10.1055/s-0035-1551853
Bibliografische Angaben
Nachweis in CareLit
Autor:innenK Gecse, K Farkas, B Lovász, J Banai, L Bene, B Gasztonyi, P Golovics, T Kristóf, L Lakatos, P Miheller, F Nagy, K Palatka, M Papp, VÁ Patai, Á Salamon, T Szamosi, Z Szepes, T Tóth, Á Vincze, T Molnár, P Lakatos
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Biosimilars are biologic medicines that enter the market subsequent to an original reference product whose patent has expired. Biosimilar infliximab entered the Hungarian market in May 2014. Few data is yet available on the safety and efficacy of biosimilar infliximab in extrapolated indications, such as inflammatory bowel diseases. Methods: A prospective, nationwide, multicentre, observational cohort…
Zitieren
Zitierempfehlung
K Gecse, K Farkas, B Lovász, J Banai, L Bene, B Gasztonyi, P Golovics, T Kristóf, L Lakatos, P Miheller, F Nagy, K Palatka, M Papp, VÁ Patai, Á Salamon, T Szamosi, Z Szepes, T Tóth, Á Vincze, T Molnár, P Lakatos (2015) Biosimilar Infliximab in inflammatory bowel diseases: First interim results from a prospective nationwide observational cohort. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0035-1551853
Mit CareLit weiterarbeiten